50297-40-0

Basic information

• Product Name: CHEMBRDG-BB 6018839
• Synonyms: CHEMBRDG-BB 6018839;3-CHLORO-N-(3-HYDROXYPHENYL)PROPANAMIDE;3-chloro-N-(3-hydroxyphenyl)propanamide(SALTDATA: FREE);3-Chloro-N-(3-hydroxy-phenyl)-propionamide
• CAS NO: 50297-40-0
• Molecular Formula: C₉H₁₀ClNO₂
• Molecular Weight: 199.63
• Mol File: 50297-40-0.mol

Chemical Properties

• Boiling Point: 429.2°C at 760 mmHg
• Flash Point: 213.4°C
• Appearance: /
• Density: 1.341g/cm³
• Vapor Pressure: 5.68E-08mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: 2-8°C
• Solubility: Dmso (Slightly), Methanol (Slightly)
• PKA: 9.52±0.10(Predicted)
• CAS DataBase Reference: CHEMBRDG-BB 6018839(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 6018839(50297-40-0)
• EPA Substance Registry System: CHEMBRDG-BB 6018839(50297-40-0)

Safety Data

• Hazardous Substances Data: 50297-40-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 6018839 is used as a drug candidate for the treatment of certain diseases or conditions due to its ability to interact with specific biological targets and modulate or block certain biological processes.
Used in Research and Development:
CHEMBRDG-BB 6018839 is used as a research tool to study its potential therapeutic applications and mechanism of action in various areas of medicine. This helps in understanding its properties and exploring its potential as a drug candidate for the treatment of specific diseases or conditions.

InChI:InChI=1/C9H10ClNO2/c10-5-4-9(13)11-7-2-1-3-8(12)6-7/h1-3,6,12H,4-5H2,(H,11,13)

Upstream product

• 625-36-5 2-chloropropionyl chloride 
• 591-27-5 m-Hydroxyaniline 

Downstream Products

• 22246-18-0 7-hydroxy-3,4-dihydro-2-(1H)-quinolinone 
• 1227513-30-5 3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(3-hydroxyphenyl)propanamide 
• 1444511-73-2 diethyl 2-[N-(3-hydroxyphenyl)carbamoyl]ethylphosphonate 
• 1444512-19-9 [N-(3-hydroxyphenyl)carbamoyl]ethylphosphonic acid 
• 1444512-66-6 sodium hydrogen [N-(3-hydroxyphenyl)carbamoyl]ethylphosphonate 
• 129722-34-5 7-(4-bromobutoxy)-3,4-dihydro-2(1H)-quinolinone 
• 70500-72-0 7-hydroxy-1H-quinolin-2-one 
• 913613-82-8 7-(4-chlorobutoxy)quinoline-2(1H)-one 
• 913611-97-9 Brexpiprazole 
• 129722-12-9 aripiprazole 

Relevant articles and documents

Preparation method of brexpiprazole intermediate 7-hydroxy-1H-quinoline-2-ketone

The invention belongs to the field of chemical engineering, and particularly relates to a preparation method of a brexpiprazole intermediate 7-hydroxy-1H-quinoline-2-ketone. According to the novel method for preparing the 7-hydroxy-1H-quinoline-2-ketone, DDQ is replaced with palladium on carbon, the obtained product is high in yield, few in impurity and easy to operate, the catalyst can be recycled, a target compound is synthesized through direct catalytic dehydrogenation, and the method has green atom economy and is suitable for industrial production.

An innovative approach for the synthesis of 7-hydroxyquinolin-2(1H)-one: A key intermediate of brexpiprazole

2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ) mediated oxidation of 7-hydroxy-1,2,3,4-tetrahydro-2-quinolinone has been prepared from 3-hydroxy aniline to obtain 7-hydroxyquinolin-2(1H)-one in aqueous media. Stoichiometric quantities of DDQ and THF provides a high out put of 7-hydroxyquinolin-2(1H)-one and reduces the consumption of organic solvents and discourages by-products. Overall advantage with this approach was reduce the time cycle and cost of the brexpiprazole intermediate.

Method for synthesizing aripiprazole

The invention discloses a method for synthesizing aripiprazole. The method comprises making 4-halogenated-3-nitrophenol react with an ethylenation reagent under palladium catalysis conditions to obtain 3-nitro-4-vinylphenol; making the 3-nitro-4-vinylphenol and 1,4-dihalogenated butane reacting with alkali to obtain 4-(4-halobutoxy)-2-nitro-1-styrene; making the 4-(4-halobutoxy)-2-nitro-1-styreneand 1-(2,3-dichlorophenyl)piperazine salt reacting with the alkali to obtain 1-(2,3-dichlorophenyl)-4-(4-(3-nitro-4-vinylphenoxy)butyl)piperazine; making the 1-(2,3-dichlorophenyl)-4-(4-(3-nitro-4-vinylphenoxy)butyl)piperazine reacting with CO to form the aripiprazole. The method for synthesizing the aripiprazole has the total yield of up to 77% and is simple in post treatment.

Design, synthesis, molecular docking, and in vitro antidiabetic activity of novel PPARγ agonist

Abstract: The present work describes the design, synthesis, molecular docking, biological evaluation, and assessment of structure–activity relationship of new derivatives based upon the molecular skeleton of the drug pioglitazone, a compound which is currently used for the management of type 2 diabetes mellitus. Pioglitazone has several side effects such as weight gain, edema, congestive heart failure, and bladder cancer. Therefore, there is a strong demand for identification of new lead candidates in the treatment of type 2 diabetes mellitus. A series of 24 compounds were prepared and evaluated for their peroxisome proliferator-activated receptor-γ (PPARγ) binding affinity assay and the IC50 values were determined. Among these compounds, six compounds exhibited promising IC50 values as compared to standard drugs pioglitazone and rosiglitazone. Furthermore, in order to confirm the target of these molecules, molecular docking study was carried out with peroxisome proliferator-activated receptor-γ (PPARγ) protein. Molecular modeling studies suggested that these compounds appropriately interact in the active sites of receptor. Graphical abstract: [Figure not available: see fulltext.].

Synthesis and antimalarial activity of N-benzylated (N-arylcarbamoyl)alkylphosphonic acid derivatives

A series of novel and readily accessible N-benzylated (N-arylcarbamoyl)alkylphosphonate esters and related compounds have been prepared as potential antimalarial agents. Bioassays reveal that some of these compounds exhibit promising activity against Plasmodium falciparum, and exhibit no significant growth inhibition of HeLa cells.

Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors

DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions.

Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates

The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.

Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia

A dihydroquinolinone moiety was found to be a potent serotonin reuptake inhibitor pharmacophore when combined with certain amines. This fragment was coupled with selected D2 ligands to prepare a series of dual acting compounds with attractive in vitro profiles as dopamine D2 partial agonists and serotonin reuptake inhibitors. Structure-activity studies revealed that the linker plays a key role in contributing to D2 affinity, function, and SRI activity.

ACTIVATIBLE DYES

Novel, activatable dyes, such as photoactivatable dyes, e.g., oxazine dyes, are described. Some of the dyes are targeting dyes that can, e.g., target biomolecules, such as polypeptides, proteins, or nucleic acids. Upon activation, such as by irradiation, the novel dyes rapidly turn on their fluorescence and emit light, such as near-IR light with spatial and temporal precision.

ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS

The invention provides compounds of the Formula: (I) that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre- menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses. The compounds are able to block the recptake of serotonin and are modulators at brain 5HT1A serotonin receptors.